AU2018334386B2 - Method and composition for treating viral infection - Google Patents

Method and composition for treating viral infection Download PDF

Info

Publication number
AU2018334386B2
AU2018334386B2 AU2018334386A AU2018334386A AU2018334386B2 AU 2018334386 B2 AU2018334386 B2 AU 2018334386B2 AU 2018334386 A AU2018334386 A AU 2018334386A AU 2018334386 A AU2018334386 A AU 2018334386A AU 2018334386 B2 AU2018334386 B2 AU 2018334386B2
Authority
AU
Australia
Prior art keywords
infection
acid
subject
antiviral composition
oleandrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018334386A
Other languages
English (en)
Other versions
AU2018334386A1 (en
Inventor
Otis C. Addington
Robert A. Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Biotechnology Inc
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/051553 external-priority patent/WO2018053123A1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of AU2018334386A1 publication Critical patent/AU2018334386A1/en
Priority to AU2020204236A priority Critical patent/AU2020204236B2/en
Application granted granted Critical
Publication of AU2018334386B2 publication Critical patent/AU2018334386B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018334386A 2017-09-14 2018-07-16 Method and composition for treating viral infection Active AU2018334386B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020204236A AU2020204236B2 (en) 2017-09-14 2020-06-25 Method and composition for treating viral infection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2017/051553 WO2018053123A1 (en) 2016-09-14 2017-09-14 Method and compositions for treating viral infection
AUPCT/US2017/051553 2017-09-14
US201862698365P 2018-07-16 2018-07-16
US62/698,365 2018-07-16
PCT/US2018/042226 WO2019055119A1 (en) 2017-09-14 2018-07-16 METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204236A Division AU2020204236B2 (en) 2017-09-14 2020-06-25 Method and composition for treating viral infection

Publications (2)

Publication Number Publication Date
AU2018334386A1 AU2018334386A1 (en) 2020-04-02
AU2018334386B2 true AU2018334386B2 (en) 2021-11-04

Family

ID=65723839

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018334386A Active AU2018334386B2 (en) 2017-09-14 2018-07-16 Method and composition for treating viral infection
AU2020204236A Active AU2020204236B2 (en) 2017-09-14 2020-06-25 Method and composition for treating viral infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020204236A Active AU2020204236B2 (en) 2017-09-14 2020-06-25 Method and composition for treating viral infection

Country Status (9)

Country Link
EP (1) EP3681508A4 (ja)
JP (3) JP6820450B2 (ja)
KR (2) KR102295179B1 (ja)
AU (2) AU2018334386B2 (ja)
CA (1) CA3075729A1 (ja)
IL (2) IL285232B (ja)
MX (1) MX2020002883A (ja)
RU (1) RU2020113341A (ja)
WO (1) WO2019055119A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7153083B2 (ja) * 2020-03-31 2022-10-13 フェニックス・バイオテクノロジー・インコーポレイテッド コロナウイルス感染を治療するための方法および組成物
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
CN114209711A (zh) * 2020-03-31 2022-03-22 菲尼克斯生物技术公司 用于治疗冠状病毒感染的方法和组合物
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
FR3109297A1 (fr) * 2020-04-19 2021-10-22 Ephyla « Nouvel inhibiteur non protéique de furine »
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
US20230310612A1 (en) * 2022-04-01 2023-10-05 Alexia Reif Anti-viral composition and method for preparing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN165073B (ja) 1986-05-13 1989-08-12 Ziya Ozel Huseyin
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
WO1999059578A1 (en) 1998-05-19 1999-11-25 Research Development Foundation Triterpene compositions and methods for use thereof
JP2002526452A (ja) 1998-09-24 2002-08-20 オゼル・ファーマスーティカルズ・インコーポレイテッド キョウチクトウ抽出物、その医薬組成物及びその調整方法
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
US6569842B2 (en) 2000-08-18 2003-05-27 Board Of Trustees Of The University Of Illinois, The Method of preparing and use of prodrugs of betulinic acid derivatives
US9931316B2 (en) * 2004-01-06 2018-04-03 Paul Edward Stamets Antiviral activity from medicinal mushrooms and their active constituents
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
CA2446748C (en) 2001-05-11 2011-03-08 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2003099011A1 (en) * 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
JP2006508126A (ja) 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006085334A2 (en) 2005-02-09 2006-08-17 Dabur Pharma Limited Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
US20090076290A1 (en) 2005-03-29 2009-03-19 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006133314A2 (en) 2005-06-08 2006-12-14 Regents Of The University Of Minnesota Synthesis of betulonic and betulinic aldehydes
KR101254938B1 (ko) 2005-06-10 2013-04-16 포라가세이고오교오가부시끼가이샤 신규 트리테르펜산 유도체 및 이를 포함하는 피부 외용제
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2633402A1 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
BRPI0820564A2 (pt) 2007-11-13 2017-05-23 Phoenix Biotechnology Inc método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US7943778B2 (en) 2008-04-18 2011-05-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
CA2736568A1 (en) 2008-09-10 2010-03-18 Universite Du Quebec A Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
WO2011064710A1 (en) 2009-11-30 2011-06-03 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US8481086B2 (en) 2010-01-11 2013-07-09 Phoenix Biotechnology, Inc. Method of treating neurological conditions with cardiac glycoside
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
PT2670764E (pt) 2011-01-31 2015-11-20 Bristol Myers Squibb Co C-28 aminas de derivados de ácido betulínico c-3 modificado como inibidores de maturação de vih
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
NO2786757T3 (ja) 2011-12-01 2018-01-13
EP2787002B1 (en) 2011-12-01 2016-06-01 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
CN104684883A (zh) 2012-08-14 2015-06-03 内克索利戈有限公司 新型乌索酸衍生物及其制备方法
EP2892911B1 (en) 2012-09-10 2017-08-30 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
KR102237359B1 (ko) 2012-09-10 2021-04-06 리아타 파마슈티컬즈, 아이엔씨. 올레아놀산의 ｃ１７―알칸디일 및 알켄디일 유도체 및 그의 사용 방법
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
KR20150121712A (ko) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
US10011838B2 (en) * 2014-02-12 2018-07-03 Novozymes Ais Yeast strain and microbial method for production of pentacyclic triterpenes and/or triterpenoids
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
WO2016200672A1 (en) * 2015-06-08 2016-12-15 Cutanea Life Sciences, Inc. Therapeutic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Also Published As

Publication number Publication date
EP3681508A1 (en) 2020-07-22
JP2021063105A (ja) 2021-04-22
CA3075729A1 (en) 2019-03-21
WO2019055119A1 (en) 2019-03-21
IL273162B (en) 2021-08-31
MX2020002883A (es) 2020-10-05
JP2022075755A (ja) 2022-05-18
IL273162A (en) 2020-04-30
AU2020204236B2 (en) 2020-12-10
IL285232B (en) 2022-07-01
JP2020534293A (ja) 2020-11-26
AU2020204236A1 (en) 2020-07-16
RU2020113341A3 (ja) 2021-10-15
KR20210107904A (ko) 2021-09-01
EP3681508A4 (en) 2021-05-19
JP7037673B2 (ja) 2022-03-16
KR20200081356A (ko) 2020-07-07
IL285232A (en) 2021-09-30
RU2020113341A (ru) 2021-10-15
KR102295179B1 (ko) 2021-08-30
JP6820450B2 (ja) 2021-01-27
AU2018334386A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
EP3512524B1 (en) Method and compositions for treating viral infection
US10596186B2 (en) Method and compositions for treating viral infections
AU2018334386B2 (en) Method and composition for treating viral infection
US10729735B1 (en) Method and compostitions for treating coronavirus infection
US11324789B2 (en) Method and compositions for treating equine encephalitis
IL291727B2 (en) Method and preparations for treating the corona virus infection
US20220047616A1 (en) Method and Compositions for Treating HTLV-1 Virus Infection
CA3091376C (en) Method and compositions for treating coronavirus infection
EP4295854A2 (en) Method and compositions for treating coronavirus infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)